SAN FRANCISCO, CA--(Marketwired - Feb 25, 2016) - Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the fourth quarter and year ended December 31, 2015.
“We are delighted with our substantial progress in 2015 on many fronts -- marked by strong worldwide net sales of XTANDI® (enzalutamide) capsules at the Astellas level, which grew 80 percent over 2014, as well as key developments that enhance the clinical understanding of enzalutamide, expand and diversify our late-stage pipeline, and help secure our plans to continue to meet the needs of underserved patient populations,” said David Hung, M.D., founder, President and Chief Executive Officer of Medivation.
